Critical Care Research Group (CCRG), The University of Queensland, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Int J Cardiol. 2013 Oct 3;168(3):1822-31. doi: 10.1016/j.ijcard.2013.07.117. Epub 2013 Aug 20.
The efficacy of transcatheter aortic valve implantation (TAVI) in high surgical risk and inoperable patients with severe aortic stenosis (AS) is rapidly gaining credibility with an ever-expanding body of supporting evidence. The potential of TAVI to be a treatment option for a significant cohort of patients with aortic stenosis has fuelled a drive for the optimum device and resulted in exponential advances in the technology with a focus on adverse event minimization and procedural simplification. Consequently, a plethora of new transcatheter valve choices are now available for clinical study or in the pipeline. The evaluation of past, current and emerging devices allows for an appreciation of the design considerations involved in this process and an insight to the future direction of the technology.
经导管主动脉瓣植入术(TAVI)在高手术风险和无法手术的重度主动脉瓣狭窄(AS)患者中的疗效,得到了越来越多证据的支持,其可信度也在不断提高。TAVI 有可能成为主动脉瓣狭窄患者的重要治疗选择,这促使人们不断努力寻找最佳器械,并使该技术取得了指数级的进步,重点是降低不良事件发生率和简化手术过程。因此,现在有大量新的经导管瓣膜可供临床研究或正在研发中。对过去、现在和新兴器械的评估,可以让我们了解这个过程中涉及的设计考虑因素,并深入了解该技术的未来发展方向。